Autologous Umbilical Cord Blood
Brain Hypoxia - Ischemia
Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Michael Cotten
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02612155CT.gov A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy | — | Completed | — | — | — |
NCT02551003CT.gov Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Hypoxia - Ischemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Umbilical Cord Blood (this asset) | Michael Cotten | P2 | CCC · 55 |
| Lacosamide | University of North Carolina, Chapel Hill | P4 | BB |
| Valproic Acid | University of North Carolina, Chapel Hill | P4 | BB |
| Fosphenytoin | University of North Carolina, Chapel Hill | P4 | B |
| Baclofen | University Hospital, Bordeaux | P2 | CCC |
| Phenobarbital | University of North Carolina, Chapel Hill | P4 | CCC |
| Methylphenidate | Massachusetts General Hospital | P1 | CC |
| Triglycerides,Medium Chain | Jens Rikardt Andersen | N/A | D |
| Oxygen | Capital Medical University | N/A | D |
+2 more in the Brain Hypoxia - Ischemia cohort
Other indications for Autologous Umbilical Cord Blood
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pediatric Arterial Ischemic Stroke | — | P1/2 | CC · 45 |
| Cerebral Infarction | — | P1/2 | CC · 43 |
| Traumatic Brain Injury | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Autologous Umbilical Cord Blood in Brain Hypoxia - Ischemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/autologous-umbilical-cord-blood-brain-hypoxia-ischemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →